{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:45:17Z","timestamp":1784090717011,"version":"3.55.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,4,12]]},"DOI":"10.1080\/14656566.2020.1714592","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T16:26:33Z","timestamp":1579537593000},"page":"629-636","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["An overview of lefamulin for the treatment of community acquired bacterial pneumonia"],"prefix":"10.1080","volume":"21","author":[{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, University Hospital Vall d\u2019Hebron, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Burgos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, University Hospital Vall d\u2019Hebron, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benito","family":"Almirante","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, University Hospital Vall d\u2019Hebron, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks001"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1554431"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2166"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2019-0027"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00358-13"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05789-11"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02380-17"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01497-17"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix132"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02106-12"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.347"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060273"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.02.007"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2067-1"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60733-4"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406330"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03602.x"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3180312cd5"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1086\/500140"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1086\/598975"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000551"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2016.00098"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1593753"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2018.04.031"},{"key":"cit0026","unstructured":"FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Food and Drug Administration; 2016 [cited 2020 Jan 4]. Available from: https:\/\/www.fda.gov\/media\/119537\/download"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv415"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1516749"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1385761"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000526"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.37.9.570"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz084"},{"issue":"2","key":"cit0034","first-page":"182","volume":"11","author":"Novak R","year":"2010","journal-title":"Curr Opin Invest Drugs"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22060996"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1458-1462.2006"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a027110"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1038\/srep39004"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02161-18"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00627-16"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02008-16"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz086"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz087"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv442"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz088"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz085"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz089"},{"key":"cit0048","unstructured":"Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta\u2122 (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP). Nabriva Therapeutics. [cited 2020 Jan 4]. Available from: https:\/\/investors.nabriva.com\/news-releases\/news-release-details\/nabriva-therapeutics-receives-us-fda-approval-xenleta"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz090"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.15468"},{"key":"cit0051","unstructured":"U.S. Food and Drug Administration. FDA approves new antibiotic to treat community-acquired bacterial pneumonia [press release]. Rockville, MD: FDA; 2019 Aug 19; [cited 2020 Jan 4]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia"},{"key":"cit0052","unstructured":"Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for Lefamulin. Nabriva Therapeutics. [cited 2019 Aug 6]. Available from: https:\/\/investors.nabriva.com\/news-releases\/news-release-details\/nabriva-therapeutics-announces-european-medicines-agency-ema"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2020.1714592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:41:48Z","timestamp":1620466908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2020.1714592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,4,12]]}},"alternative-id":["10.1080\/14656566.2020.1714592"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2020.1714592","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}